Open Access

Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance

  • Authors:
    • Ya-Jing Zhang
    • Chen-Lei Wen
    • Yu-Xin Qin
    • Xiao-Mei Tang
    • Min-Min Shi
    • Bai-Yong Shen
    • Yuan Fang
  • View Affiliations

  • Published online on: October 12, 2017     https://doi.org/10.3892/or.2017.6026
  • Pages:3335-3346
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Pancreatic cancer is one of the most fatal types of cancer and is associated with a dismal prognosis. Gemcitabine-based chemotherapy is clinically used for the treatment of advanced pancreatic cancer. However, many forms of pancreatic cancer have acquired resistance to gemcitabine. In order to prevent patients from suffering from the side effects of chemotherapy and to have the chance to receive more effective intervention, assessment of whether the patient pancreatic cancer cells are resistant to gemcitabine before clinical practice is crucial. Recently, patient-derived xenograft (PDX) models have been regarded as a practical approach for preclinical drug resistance test. In the present study, we harvested tumor specimens from 28 pancreatic cancer patients to establish PDX models. The tumor formation rate of the xenografts was 100%, several of which could be re-implanted in nude mice for more than 10 passages. Primary cells were further obtained from the PDX xenografts to determine their morphological features and evaluate their proliferation rate, migration capacity and angiopoietic ability. In addition, the sensitivities of the primary cells and PDX xenografts to gemcitabine were correlated with each other. When compared to the gemcitabine-sensitive cells, the gemcitabine-resistant cells had a higher level of MCF2L expression, suggesting that MCF2L plays an important role in gemcitabine resistance.

Related Articles

Journal Cover

December 2017
Volume 38 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, Y., Wen, C., Qin, Y., Tang, X., Shi, M., Shen, B., & Fang, Y. (2017). Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Oncology Reports, 38, 3335-3346. https://doi.org/10.3892/or.2017.6026
MLA
Zhang, Y., Wen, C., Qin, Y., Tang, X., Shi, M., Shen, B., Fang, Y."Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance". Oncology Reports 38.6 (2017): 3335-3346.
Chicago
Zhang, Y., Wen, C., Qin, Y., Tang, X., Shi, M., Shen, B., Fang, Y."Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance". Oncology Reports 38, no. 6 (2017): 3335-3346. https://doi.org/10.3892/or.2017.6026